TB DOT works when the dose becomes a supported appointment, not a private promise

The image fits the article because DOT works best as a repeated care appointment: medication, records, side-effect checks, dignity, and practical support have to stay in the same loop.

Directly observed therapy, or DOT, can sound punitive if it is reduced to one sentence: someone watches a tuberculosis patient swallow pills. That version is too thin. It misses why DOT became important, why it can fail, and why video DOT now counts as equivalent to in-person DOT in U.S. guidance. The useful way to read DOT is not as surveillance for its own sake. It is a treatment-delivery mechanism for a disease whose cure depends on many ordinary doses taken over a long enough calendar.[1][2][4]

Tuberculosis exposes a weakness in the word "prescription." A clinician can prescribe a regimen in one visit, but drug-susceptible TB treatment commonly runs for 6 months or more, and CDC materials describe completion windows that may extend a standard 6-month regimen within a 9-month program frame when dose timing has to be managed.[2][6] Missed doses are not just a paperwork defect. CDC's 2023 vDOT recommendation warns that interruptions can contribute to suboptimal drug concentrations, acquired resistance, longer treatment, treatment failure, and recurrence.[4] DOT exists because TB treatment is not finished when the bottle leaves the clinic.

Timeline anchors

2006: WHO's Stop TB Strategy built on DOTS and moved the older DOTS frame toward patient-centered treatment and broader TB/HIV and drug-resistant TB goals.[1]
2010: WHO's fourth-edition TB treatment guideline described major global TB-control progress after widespread DOTS implementation, while also revising treatment recommendations through systematic-review methods.[1]
2015: a Cochrane review of 11 randomized controlled trials including 5,662 people with TB cautioned that direct observation by itself did not reliably beat self-administered therapy across trial settings.[3]
2022: a New York City randomized noninferiority trial, later summarized by CDC, compared electronic and in-person observation over 8-week crossover periods and found observed-dose proportions of 89.8% for vDOT and 87.2% for in-person DOT.[4]
2023: CDC updated U.S. recommendations to treat video DOT as equivalent to in-person DOT for people undergoing treatment for diagnosed TB when the patient's situation and program capacity fit.[4]

The mechanism is a loop, not a watcher

The narrowest mechanism of DOT is direct verification: a trained observer sees medication ingestion and records it. That matters because a TB program cannot manage what it never sees. But the clinical mechanism is wider. CDC's drug-susceptible TB treatment page describes DOT as observation that also monitors adverse events and provides social support.[2] The 2023 MMWR says the same thing more explicitly: during DOT, health workers observe ingestion, monitor for adverse events, and support completion.[4]

Those extra clauses are not soft additions. They are the part that turns observation into care. A patient may miss doses because of nausea, stigma, work schedules, transportation costs, housing instability, depression, confusion about pill burden, or fear of side effects. A program that only confirms "yes" or "no" has built a compliance meter. A program that asks what happened, notices symptoms, rearranges the meeting place, and coordinates refills has built a treatment loop.[2][4]

That distinction also explains the Cochrane caution. Karumbi and Garner's 2015 review evaluated DOT against self-administered therapy and concluded that randomized trials did not show a consistent cure or completion advantage for DOT alone.[3] This is not a reason to dismiss DOT. It is a reason to be precise about what makes DOT work. If the encounter adds burden without solving the patient's real barriers, it can become another obstacle. If the encounter bundles observation with case management, convenience, side-effect triage, incentives, enablers, and rapid rescue after missed doses, it becomes a delivery system.[2][3][4][6]

Why TB makes adherence different from ordinary remembering

Many medicines suffer from imperfect adherence. TB is different because the consequences are social as well as individual. Active pulmonary TB can spread through the air, and an incomplete regimen can leave the patient uncured while also increasing the risk of resistance.[4][6] That makes treatment completion a public-health event, not only a private behavior.

The long duration creates a second problem: the patient often starts to feel better before the regimen is finished. A symptom-driven mental model says, "I am improving, so the job is done." TB treatment asks for a bacteriologic mental model instead: the job is done when the regimen has delivered enough active drug exposure over enough time to prevent relapse, resistance, and ongoing transmission.[2][4] DOT makes that invisible timetable visible. Each observed dose becomes one small appointment with the full treatment plan.

The point is not that patients cannot be trusted. The point is that TB care is asking people to sustain a difficult routine through normal life while the public-health system has a duty to close gaps early. That is why the most defensible DOT programs should feel less like suspicion and more like accompaniment: flexible location, clear explanation, attention to side effects, and a route back into care when a dose is missed.[2][4]

Video DOT changes the friction, not the clinical aim

Video DOT is important because it tests whether the mechanism depends on physical co-presence. CDC's 2023 recommendation says it does not have to. The agency reviewed evidence on adherence, completion, and microbiologic resolution and concluded that vDOT should be considered equivalent to in-person DOT for diagnosed TB treatment.[4] The aim stays the same: verify ingestion, monitor problems, support completion, and keep a record.[4][6]

The advantage is friction. In-person DOT can collide with work, school, transportation, weather, stigma, and staff travel. The MMWR notes that community visits can create unwanted questions from neighbors or coworkers; CDC's case-study page adds that video observation can save staff time and patient travel costs.[4][6] In the CDC summary of New York City data, 61 patients on eDOT and 329 on in-person DOT had similar treatment completion, 96% and 97%, while scheduled-session maintenance was 95% and 91%.[6]

California's five-district experience sharpens the same lesson. That Emerging Infectious Diseases study compared 274 patients using video DOT with 159 using in-person DOT and treated VDOT as a way to reduce cost, travel, stigma, and mobility barriers while preserving communication between patient and program.[5] The operational insight is simple: if the hardest part is not swallowing one pill but sustaining months of observed, documented care, then convenience is not a luxury. It is part of the mechanism.

Still, video is not magic. CDC warns that in-person DOT may be better for patients receiving injectable medications, people who are medically fragile, people who are not adhering with vDOT, or those who cannot use the technology comfortably.[4] Recorded videos also create verification questions: Was the full dose swallowed? Did the patient stop the recording too soon? Can the program respond quickly if side effects appear?[4] vDOT succeeds only when the remote workflow preserves the clinical functions that made DOT worth doing in the first place.

The boundary: DOT is not the whole TB program

The cleanest conclusion is also the most practical one. DOT is neither a miracle ingredient nor an ethical mistake by default. It is a control point inside a broader TB program. WHO's treatment guideline places DOTS inside a larger structure of national-program design, patient-centered treatment, drug resistance, TB/HIV coordination, and systematic recommendations.[1] CDC places DOT inside regimen selection, dose timing, adverse-event monitoring, and public-health case management.[2][4]

That boundary matters because "watched swallowing" is too small a theory of cure. TB treatment depends on the right drugs, the right duration, susceptibility information, side-effect management, follow-up cultures when needed, and a program that can distinguish an isolated missed appointment from a collapsing regimen.[2][4] DOT gives the program a repeated point of contact. It does not replace the program.

The better slogan, then, is not "watch the patient." It is "keep the regimen alive." For tuberculosis, a dose is not merely a pill entering a mouth. It is a recorded event in a long chain of treatment. DOT works when that event becomes an opening for support, adjustment, and accountability. It fails when observation becomes the whole intervention.

cronfeed.work